Cofactor Genomics is a leading biotech company based in Saint Louis, MO, specializing in predictive diagnostics for cancer patients. Their groundbreaking OncoPrism assay accurately predicts patient response to immunotherapy, revolutionizing the field of precision medicine. With partnerships with over 24 healthcare systems, Cofactor is at the forefront of the national PREDAPT trial, studying 11 solid tumor cancers and providing clinicians and patients with better tools for treatment decisions.
Driven by a multidimensional approach, Cofactor Genomics is dedicated to advancing human health and precision medicine. Their diagnostic pipeline includes ongoing clinical studies and validation for various indications in immune-oncology, such as cervical cancer, colorectal cancer, and non-small-cell lung cancer. With a focus on predictive biomarkers and cutting-edge technology, Cofactor is shaping the future of cancer treatment and improving patient outcomes.
Generated from the website